Cambridge Healthtech Institute’s 4th Annual

Emerging Targets for Immunomodulatory Antibodies and Combinations

Novel Targets and Pathways for Cancer Immunotherapy and Combinations

August 11-12, 2020



While cancer immunotherapy has made a giant leap in the past five years, the majority of therapies at advanced stages of development are clustered in a similar target space. The increased investment in immuno-oncology has created an urgent opportunity to discover and populate new target spaces that either present new classes of immunotherapies or can be used in combination with existing products. Cambridge Healthtech Institute’s Fourth Annual Emerging Targets for Immunomodulatory Antibodies and Combinations conference will cover the emerging target space, including immunomodulatory inhibitor and agonist targets, stromal and immune cell targets, and strategies for rational combination immunotherapy. Case studies of preclinical and translational approaches to the discovery and validation of new immuno-oncology targets and combinations will be presented.

Preliminary Agenda

COMBINATION STRATEGIES TO OVERCOME RESISTANCE TO IMMUNOTHERAPY

Targeting a Tumor-Intrinsic PD-L1-NLRP3 Signaling Pathway to Overcome Adaptive Resistance to Anti-PD-1 Antibody Immunotherapy

Brent Hanks, MD, PhD, William Dalton Family Assistant Professor, Medical Oncology; Assistant Professor, Department of Pharmacology and Cancer Biology; Associate Director of Basic and Translational Research, Duke Center for Cancer Immunotherapy; Duke University, Duke Cancer Institute

Talk Title to be Announced

Maria Karasarides, PhD, Executive Director, Immuno-Oncology, Regeneron Pharmaceuticals

Priming Neoantigen Specific T Cells Utilizing Tumor Extracellular Vesicles

Fredrika Carlsson, PhD, Senior Scientist, Alligator Bioscience

Therapeutic Potential of Cargo-ARMED Next Generation VSV-GP Variants and Combinatorial Approaches with Immune Modulators

Philipp Müller, PhD, Senior Principal Scientist, Cancer Immunology, Boehringer Ingelheim

Preventing or Reversing Tumor Evolution to Enhance Current Targeted and Immune-Based Therapies in Breast Cancer

Nathaniel Wang, PhD, President and CSO, Replicate Bioscience, Inc.

TARGETING INNATE IMMUNITY

Targeting Soluble NKG2D Ligands to Remodulate Tumor Microenvironment and Enhance the Response to Immunotherapy

Jennifer Wu, PhD, Mary and Patrick Scanlan Professor of Urology, Professor of Immunology, Feinberg School of Medicine, Robert Lurie Comprehensive Cancer Center, Northwestern University

Talk Title to be Announced

Jon Wigginton, MD, Senior Vice President, Clinical Development & CMO, MacroGenics

PLENARY KEYNOTE SESSION

PD-1 Antibodies Either as Monotherapy or Precision Medicine Informed Combinations are Transforming Cancer Care

Roy Baynes, MD, PhD, Senior Vice President and Head, Global Clinical Development, CMO, Merck Research Laboratories

EMERGING CHECKPOINT INHIBITOR TARGETS: DISCOVERY, PRECLINICAL, AND TRANSLATIONAL APPROACHES

New Immune Checkpoints: From Discoveries to Clinical Trials

XingXing Zang, PhD, Professor and Louis Goldstein Swan Chair, Albert Einstein College of Medicine

TIM-3 Antibody for Immuno-Oncology

Xiaomo Jiang, PhD, Principle Scientist II, Immuno-Oncology, Novartis Institutes for BioMedical Research

Preclinical Identification and Validation of Immuno-Oncology Targets

Marcus Bosenberg, MD, PhD, Professor of Dermatology, Pathology, and Immunobiology; Interim Director, Yale Center for Immuno-Oncology; Director, Center for Precision Cancer Modeling, Yale University




For more details on the conference, please contact:

Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com

For partnering and sponsorship information, please contact:

Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com


Connect With Us

MEETING SUGGESTIONS

For meeting questions or suggestions, please contact:

Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
juliab@healthtech.com

PARTNERING & SPONSORSHIP

For partnering and sponsorship info, please contact:

Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
+1 781.247.6286
reymael@healthtech.com

MEDIA & ASSOCIATION

For media and association partnerships, please contact:

Pete DeOlympio
Sr. Marketing Manager
Cambridge Healthtech Institute
+1 781.972.5415
peted@healthtech.com